Natural history of node-negative breast cancer: Are conventional prognostic factors predictors of time to relapse?

Breast

Volumn 11, Issue 5, 2002, Pages 442-448

  Héry, Michel ⁱ   Delozier, Thierry ^a   Ramaioli, Alain ^b   Julien, Jean Pierre ^c   de Lafontan, Brigitte ^d   Petit, Thierry ^e   de Ghislain, Catherine ^f   Weber, Béatrice ^g   Bonneterre, Jacques ^h   Teissier, Eric ^b  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE PAUL STRAUSS   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FAMILY HISTORY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT CODING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; TIME; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 0036817090     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2002.0462     Document Type: Article

References (38)

1. Carter C L, Allen C, Henson D E. Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.
2. Rosen P P, Groshen S, Kinne D W, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11: 2090-2100.
3. Rosen P P, Groshen S, Saigo P E, Kinne D W, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 17: 1239-1251.
4. Bloom H J G, Richardson W W. Histological grading and prognostic in breast cancer: a study of 1409 cases of which 359 followed for 15 years. Br J Cancer 1957; 11: 359-377.
5. Fisher B, Redmond C, Fisher E R, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicator of prognosis in node negative breast cancer patients: findings from National Surgical adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 1076-1087.
6. Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population based case-control study. Cancer 1985; 55: 643-647.
7. De La Rochefordièe A, Asselain B, Campana F et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-1043.
8. Fowble B L, Schultz D J, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994; 30: 22-23.
9. Karrison T G, Ferguson D J, Meier P. Dormancy of mammary carcinoma after mastectomy. JNCI 1999; 91: 80-85.
10. Valagussa P, Bonnadonna. G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 1978; 41: 1170-1178.
11. Baum M, Chaplain M A, Anderson A R, Douek M, Vaidya J S. Does breast cancer exist in a state of chaos? Eur J Cancer 1999; 35: 886-891.
12. Rank F, Dombernowsky P, Jespersen N C, Pedersen B V, Keiding N. Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. Cancer 1987; 60: 1299-1305.
13. Clayton F. Pathological correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68: 1309-1317.
14. Le Doussal V, Tubiana-Hulin M, Hacene K, Friedman S, Brunet M. Nuclear characteristics as indicators of prognosis in node negative breast cancer patients. Breast Cancer Res Treat 1989; 14: 207-216.
15. Huseby R A, Ownby H E, Frederick J, Brooks S, Russo J, Brennan M J. Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: variables associated with disease recurrence and survivorship. J Clin Oncol 1988; 6: 83-88.
16. Hery M, Oioanni L, Lalanne C M, Namer M, Courdi A. The DNA labelling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 1987; 9: 207-211.
17. Silvestrini R, Diadone M O, Di Fronzo O, Morabito A, Valagussa P, Bonadonna O. Prognostic implication of labelling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 1986; 7: 161-169.
18. Silvestrini R, Diadone M O, Oasparini O. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 1985; 56: 1982-1987.
19. Hartveit F, Maehle B O, Pettersen K C. Size of breast carcinomas at operation related to tumour growth rate. Breast Cancer Res Treat 1987; 10: 47-50.
20. Breast Cancer Study Group. Identification of breast cancer patients with high risk of early recurrence after radical mastectomy. II. Clinical and pathological correlations. A report of the primary therapy of Breast Cancer Study Group. Cancer 1978; 42: 2809-2826.
21. Retsky M W, Demicheli R, Swartzendruber D E et al. Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 1997; 45: 193-202.
22. Albain K S, Allred D C, Clark O M. Breast cancer outcome and predictors of outcome: are there age differentials? JNCI Monogr 1994; 16: 35-42.
23. Wilking N, Rutqvist L E, Nordenskjold B, Skoog L. Steroid receptor levels in breast cancer. Relationships with age and menopausal status. Acta Oncol 1989; 128: 807-810.
24. Butler L A, Bretsky S, Menendez-Botet C, Kinne D W. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 1985. 55: 1178-1181.
25. Nomura Y, Miura S, Koyama H et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer 1992; 69: 153-164.
26. Raemaekaers J M, Beex L V, Koenders A J et al. Disease-free interval and estrogen receptor activity in tumour tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985; 6: 123-130.
27. Heimann R, Ferguson D, Powers C, Heilman S. Angiogenesis and estrogen receptor in young women with breast cancer. Int Radiat Oncol Biol Phys 1997; 39: 136.
28. McGuire W L, Clark G M, Dressler L G, Owens M A. Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1986; 1: 19-25.
29. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 765-772.
30. Rauschecker H F, Sauerbrei W, Gatzemeir W et al. Eight-year results of a prospective non-randomized study on therapy of small breast cancer. The German Breast Cancer Study Group (GBSG). Eur J Cancer 1998; 34: 315-323.
31. Handley R S. A surgeon’s view of the spread of breast cancer. Cancer 1969; 24: 1231-1234.
32. Veronesi U, Valagussa P. Ineffecacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47: 170-175.
33. Demicheli R, Valagussa P, Foroni E, Bonadonna. G. Mean relapse rate per year (MRR/Y) suggests different biological conditions of breast cancer micrometastases at the time of primary local-regional treatment. Proc Am Soc Clin Oncol 1993; 112: 119.
34. Galea M H, Blamey R W, Elston C E, Ellis I O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3): 207-219.
35. Goldhirsch A, Wood W C, Senn H J, Glick J H, Gelbert R D. Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 1995; 31A: 1754-1759.
36. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-1894.
37. Pantel K, Cote R J, Fodstad O. Detection and clinical importance of micrometastatic disease. 1999; 91: 1113-1124.
38. Stewart J F, King R J, Sexton S A, Millis R R, Rubens R D, Hayward J L. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17: 449-453.